Every Form 4 that Marchex, Inc. (MCHX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MCHX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCHX filings page.
Marchex, Inc. chairman and ten percent owner Russell C. Horowitz reported receiving $4,864,865 of 6.0% convertible debt due 2028 in connection with Marchex’s acquisition of privately held Archenia, Inc. The notes were granted on July 1, 2026 under a stock purchase agreement.
The convertible notes bear 6% interest and are payable in three equal tranches on the 12-, 18- and 24-month anniversaries of the closing. They are convertible into up to 2,702,703 shares of Marchex Class B common stock at $1.80 per share. The agreement also entitles Horowitz to receive 972,973 additional shares for each of the first and second 12‑month periods after closing if Archenia meets specified revenue or Adjusted EBITDA thresholds and integration or customer retention targets, with this earn-out right fixed and irrevocable as of the closing date.
Marchex, Inc. reported that vice chairman Michael A. Arends acquired $4,144,144 of 6.0% convertible debt due 2028 from the company in connection with Marchex’s purchase of 100% of Archenia, Inc.
The notes pay 6% interest in three equal principal tranches on the 12-, 18- and 24‑month anniversaries of the July 1, 2026 closing. They are convertible, in whole or in part, into Class B common stock at $1.80 per share, covering 2,302,302 underlying shares.
The stock purchase agreement also grants Arends an earn-out right to receive up to 828,829 additional shares for each of the first and second 12‑month periods after closing if Archenia’s revenue or Adjusted EBITDA exceed prior‑period levels and it meets specified integration or customer retention targets. The right to receive these additional shares became fixed and irrevocable on the closing date.
Marchex Inc. President & Chief Revenue Officer Troy Hartless exercised restricted stock units and received Class B common shares. On March 20, 2026, 87,500 restricted stock units converted into 87,500 shares of Class B Common Stock at a price of $0.00 per share. These units were granted effective March 20, 2025 and vested in full on the first anniversary of the grant date, making this a compensation-related equity delivery rather than an open-market purchase or sale. Following the conversion, this award’s derivative position is fully exercised and Hartless holds 87,500 Class B shares from this grant.
Marchex Inc Chief Financial Officer Brian Nagle exercised 7,500 restricted stock units into 7,500 shares of Class B Common Stock. The Form 4 shows a derivative exercise (code M) on March 20, 2026 at a stated price of $0.00 per unit.
According to the footnote, these restricted stock units were granted effective March 20, 2025 and vested in full on the first anniversary of the grant date. After the settlement, Nagle directly holds 7,500 shares of Class B Common Stock and no remaining units from this award. The filing reports no share sales or tax-withholding dispositions, indicating a routine compensation-related vesting and share issuance.
Marchex Inc. Chief Operating Officer & CLO Francis J. Feeney exercised 62,500 restricted stock units into the same number of Class B Common Stock shares. The units, granted effective March 20, 2025, vested in full on the first anniversary and converted at a zero exercise price as part of his equity compensation.
Nagle Brian reported acquisition or exercise transactions in this Form 4 filing.
Marchex Inc Chief Financial Officer receives new equity award. Brian Nagle was granted 56,089 restricted stock units effective February 17, 2026. The award was recorded at a price of $0.00 per unit, reflecting a non-cash grant.
Each restricted stock unit represents the right to receive one share of Marchex Class B common stock upon vesting. The units vest in full on the first anniversary of the grant date, meaning all 56,089 units are scheduled to vest one year after February 17, 2026, if conditions are met.
Marchex Inc reported an equity compensation grant to a senior executive. President & Chief Revenue Officer Troy Hartless acquired 128,205 restricted stock units effective February 17, 2026. Each unit represents one share of Class B common stock and will vest in full on the first anniversary of the grant date, increasing his direct equity-based stake if vesting conditions are satisfied.
Feeney Francis J reported acquisition or exercise transactions in this Form 4 filing.
Marchex Inc. reported that Chief Operating Officer & Chief Legal Officer Francis J. Feeney received a grant of 96,153 restricted stock units effective February 17, 2026. Each unit represents one share of Class B common stock and will vest in full on the first anniversary of the grant date, aligning his compensation with future company performance.
Marchex Inc (MCHX) director receives new stock option grant. A company director was granted an employee stock option to buy 50,000 shares of Marchex Class B Common Stock at an exercise price of $1.64 per share, effective December 16, 2025. The option expires on December 16, 2035.
According to the vesting terms, 50% of the options vest on December 16, 2026 and the remaining 50% vest on December 16, 2027, assuming the director continues to serve on the Board through those dates. All of the options vest in full upon a Change of Control as defined in the director’s option agreement.
Marchex Inc. reported that one of its directors received an employee stock option grant for 50,000 shares of Class B common stock. The option has an exercise price of $1.64 per share and expires on December 16, 2035, and is held as a direct ownership position.
The grant was effective on December 16, 2025. Half of the options vest on December 16, 2026 and the remaining half on December 16, 2027, assuming the director continues service on the board through those dates. All of the options will vest in full upon a Change of Control, as defined in the director’s option agreement.
Marchex Inc. reported an insider equity award for Vice Chairman and director Michael A. Arends. On December 16, 2025, he received an employee stock option granting the right to buy 50,000 shares of Class B common stock at an exercise price of $1.64 per share, expiring on December 16, 2035. The filing states that 50% of these options vest on December 16, 2026 and the remaining 50% on December 16, 2027, assuming continued service on the board during that period. All of the options will vest in full upon a defined Change of Control under his option agreement.
Marchex Inc director reports new stock option grant. A board member of Marchex Inc (MCHX) filed details of an equity award dated December 16, 2025. The filing shows an employee stock option to buy 50,000 shares of Class B common stock at an exercise price of $1.64 per share, expiring on December 16, 2035.
According to the disclosure, 50% of the options vest on December 16, 2026 and the remaining 50% vest on December 16, 2027, assuming the director continues serving on the board through those dates. All of the options vest in full upon a Change of Control as defined in the director’s option agreement.
Marchex Inc. disclosed that its chairman, who is also a director and 10% owner, received an employee stock option grant. On 12/16/2025, this insider was granted options to buy 50,000 shares of Class B common stock at an exercise price of $1.64 per share, expiring on 12/16/2035. Half of the options vest on December 16, 2026 and the remaining half on December 16, 2027, assuming continued service on the board. All of the options will vest in full upon a Change of Control as defined in the option agreement.
Marchex (MCHX) reported insider equity awards for its Chief Financial Officer dated 10/16/2025. The filing shows 125,000 restricted stock units tied to Class B Common Stock, which vest in full on the fourth anniversary of the grant date. It also lists 125,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest 25% on the first anniversary, then quarterly over the following three years in equal 6.25% increments.
Marchex (MCHX) reported an insider equity grant to its Chief Operating Officer & CLO. On 10/16/2025, the executive received 150,000 restricted stock units, each settling into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date.
On the same date, the executive was also granted 150,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest over four years: 25% on the first anniversary, then quarterly in equal 6.25% increments over the next three years.
Marchex (MCHX) filed a Form 4 reporting equity awards to its President & Chief Revenue Officer effective October 16, 2025. The filing discloses 150,000 restricted stock units, each convertible into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date. It also reports stock options for 150,000 shares at an exercise price of $1.81 per share, expiring October 16, 2035, vesting 25% on the first anniversary and the remainder in equal quarterly installments over the next three years.